Summit Therapeutics INC 8-K filings

Summit Therapeutics announces the initiation of a global Phase II/III HARMONi-GU1 trial for ivonescimab in first-line bladder cancer, expanding its development program.

Summit Therapeutics Inc. has entered into a distribution agreement with J.P. Morgan Securities LLC to offer and sell up to $380 million of its common stock.

Summit Therapeutics announced its second quarter 2026 financial results and provided an operational update, highlighting positive clinical data for its investigational drug ivonescimab.

Summit Therapeutics announced updated overall survival results from its Phase III HARMONi trial, showing consistent efficacy for ivonescimab in lung cancer patients.

Summit Therapeutics shareholders approved the election of nine directors and an 8 million share increase to the 2020 Stock Incentive Plan.

Summit Therapeutics Inc. has withdrawn its previously announced underwritten public offering of securities due to unfavorable market conditions.

Summit Therapeutics Inc. announced that its Audit Committee and independent directors have approved affiliates to purchase shares under its at-the-market offering, with key executives indicating potential personal purchases.

Summit Therapeutics announced new Phase II data for ivonescimab in metastatic colorectal cancer and positive Phase III results in squamous NSCLC.

Summit Therapeutics reports Q1 2026 financial results and provides clinical progress updates on its lead bispecific antibody, ivonescimab.

Summit Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting significant clinical advancements for its lead drug candidate, ivonescimab, including a BLA acceptance by the FDA.

The FDA has accepted Summit Therapeutics' Biologics License Application for ivonescimab in EGFR-mutated NSCLC, setting a PDUFA goal date of November 14, 2026.

Summit Therapeutics has submitted a Biologics License Application to the U.S. FDA for ivonescimab in EGFRm NSCLC and announced a clinical trial collaboration with GSK, while reporting a strong cash balance of $710 million.

Summit Therapeutics' partner Akeso announced positive Phase III HARMONi-A trial results for ivonescimab, demonstrating a statistically significant overall survival benefit in EGFR-mutated NSCLC patients.

Summit Therapeutics Inc. announced a $500 million private placement to fund the clinical development of its lead oncology asset, ivonescimab, with significant participation from insiders and leading biotech institutional investors.

Summit Therapeutics announced positive Phase III clinical trial results for ivonescimab in NSCLC and initiated a new global Phase III study in colorectal cancer, alongside its Q3 2025 financial report.

Summit Therapeutics announced longer-term follow-up data from its Phase III HARMONi trial for ivonescimab in EGFR-mutated NSCLC, showing an improving trend in overall survival for Western patients.

Summit Therapeutics reported strong clinical trial results for its lead drug candidate ivonescimab and announced a new $360 million at-the-market equity offering.

Summit Therapeutics Inc. amended its distribution agreement with J.P. Morgan Securities LLC to increase its at-the-market equity offering program by an additional $360 million, bringing the total potential raise to $450 million.

Summit Therapeutics Inc. has entered into a sub-sublease agreement for 36,406 square feet of office space in Palo Alto, California, with an average annual lease payment of approximately $2.8 million, commencing January 1, 2026.

Summit Therapeutics Inc. announced that all proposals, including the election of nine directors, ratification of PricewaterhouseCoopers LLP, and advisory approval of executive compensation, were approved by stockholders at its 2025 Annual Meeting.

Summit Therapeutics announced topline results from its HARMONi Phase III clinical trial for ivonescimab, demonstrating a statistically significant improvement in progression-free survival for EGFR-mutated non-small cell lung cancer patients, though overall survival showed only a positive trend without statistical significance.

Summit Therapeutics announces its Q1 2025 financial results and highlights the operational progress of ivonescimab, including positive clinical trial outcomes and regulatory approvals in China.

Summit Therapeutics announces its partner Akeso received approval from Chinese authorities for a second indication of ivonescimab and reported positive overall survival trends in a Phase III trial.

Akeso, partner of Summit Therapeutics, reports that ivonescimab in combination with chemotherapy demonstrated statistically significant superiority in progression-free survival compared to tislelizumab in treating squamous NSCLC in the HARMONi-6 Phase III trial.

Summit Therapeutics announces its Q4 and full-year 2024 financial results, highlighting progress in ivonescimab clinical trials and a new collaboration with Pfizer.

Summit Therapeutics has approved significant cash bonuses for its CEO and CFO, increased their base salaries, and reported a preliminary cash balance of approximately $412 million as of December 31, 2024.

Summit Therapeutics announced a preliminary cash balance of at least $410 million as of December 31, 2024, and highlighted significant progress in the clinical development of their lead drug candidate, ivonescimab.

Summit Therapeutics announced positive results from a Phase III trial for their drug ivonescimab, along with a $235 million private financing round.

Summit Therapeutics has successfully raised $235 million through a private placement of common stock, with significant participation from company insiders and leading biotech institutional investors.

Summit Therapeutics reported that ivonescimab significantly improved progression-free survival compared to pembrolizumab in patients with PD-L1 positive advanced non-small cell lung cancer.